SPI 119
Alternative Names: CD4 liposomal; liposome-CD4 technology; RBC CD4 liposomalLatest Information Update: 26 Feb 2008
Price :
$50 *
At a glance
- Originator Sheffield Pharmaceuticals
- Developer ALZA Corporation
- Class Antivirals
- Mechanism of Action CD4 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 28 Jun 2001 ALZA Corporation has been acquired by Johnson & Johnson
- 07 Sep 2000 Sheffield Pharmaceticals is no longer involved in the development of SPI 119
- 23 Apr 1999 Sequus has been merged into ALZA Corporation